Recommendations for the use of botulinum toxin type A in the management of cerebral palsy

Forssberg, 1997, Botulinum toxin treatment in cerebral palsy: intervention with poor evaluation?, Dev. Med. Child Neurol., 39, 635, 10.1111/j.1469-8749.1997.tb07501.x Ahnert-Hilger, 1995, Molecular aspects of tetanus and botulinum neurotoxin poisoning, Prog. Neurobiol., 46, 83, 10.1016/0301-0082(95)00003-E Blasi, 1993, Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25, Nature, 365, 160, 10.1038/365160a0 Dolly, 1994, Probing the process of transmitter release with botulinum and tetanus neurotoxins, Semin. Neurosci., 6, 149, 10.1006/smns.1994.1020 Borodic, 1994, Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections, Mov. Disord., 9, 31, 10.1002/mds.870090106 De Paiva, 1999, Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals, Proc. Natl. Acad. Sci. USA, 96, 3200, 10.1073/pnas.96.6.3200 Angaut-Petit, 1990, Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features, Neuroscience, 37, 799, 10.1016/0306-4522(90)90109-H Borodic, 1994, Botulinum toxin potency: a mystery resolved by the median paralysis unit, J. R. Soc. Med., 87, 571 First, 1994, Dose standardisation of botulinum toxin, Lancet, 343, 1035, 10.1016/S0140-6736(94)90153-8 Wohlfarth, 1997, Botulinum A toxins: units versus units, Naunyn-Schmiedeberg’s Arch. Pharmacol., 355, 335, 10.1007/PL00004951 Sampaio, 1997, DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A — Dysport and BOTOX — assuming a ratio of 4:1, Mov. Disord., 12, 1013, 10.1002/mds.870120627 Cosgrove, 1994, Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse, Dev. Med. Child Neurol., 36, 379, 10.1111/j.1469-8749.1994.tb11863.x Koman, 1994, Management of spasticity cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial, J. Pediatr. Orthop., 14, 299, 10.1097/01241398-199405000-00005 Corry, 1997, Botulinum toxin A in the hemiplegic upper limb: a double-blind trial, Dev. Med. Child Neurol., 39, 185, 10.1111/j.1469-8749.1997.tb07408.x Cosgrove, 1994, Botulinum toxin in the management of the lower limb in cerebral palsy, Dev. Med. Child Neurol., 36, 386, 10.1111/j.1469-8749.1994.tb11864.x Sutherland, 1996, Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study, Gait Posture, 4, 269, 10.1016/0966-6362(95)01054-8 Corry, 1998, Botulinum toxin A compared with stretching casts in the treatment of spastic equinus, a randomised prospective trial, J. Pediatr. Orthop., 18, 304, 10.1097/00004694-199805000-00006 Wiegand, 1976, 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection, Naunyn-Schmiedeberg’s Arch. Pharmacol., 292, 161, 10.1007/BF00498587 Wellhöner, 1973, Local tetanus in cats: neuropharmacokinetics of 125I-tetanus toxin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 276, 375, 10.1007/BF00499890 Wellhöner, 1973, Local tetanus in cats: the influence of neuromuscular activity on spinal distribution of 125I-labelled tetanus toxin, Naunyn-Schmiedeberg’s Arch. Pharmacol., 276, 387, 10.1007/BF00499891 Aoki, 1997, Botulinum toxin type A: from toxin to therapeutic agent, Eur. J. Neurol., 4, S1 Boyd, 1996, Transient urinary incontinence after botulinum A toxin, Lancet, 348, 481, 10.1016/S0140-6736(05)64586-2 Göschel, 1997, Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies — therapeutic consequences, Exp. Neurol., 147, 96, 10.1006/exnr.1997.6580 Anderson, 1992, Botulinum toxin treatment of spasmodic torticollis, J. R. Soc. Med., 85, 524, 10.1177/014107689208500906 Biglan, 1986, Absence of antibody production in patients treated with botulinum A toxin, Am. J. Ophthalmol., 101, 232, 10.1016/0002-9394(86)90601-X Brin, 1987, Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm, Mov. Disord., 2, 237, 10.1002/mds.870020402 Cole R, Cohen L, Hallett M. Local treatment of hand cramps with botulinum toxin (BOTOX). Neurology 1991;41:291 (Abstract). Cole, 1991, Treatment of musicians cramp with botulinum toxin, Med. Probl. Perform. Art, 6, 137 Erbguth F. Botulinum-toxin in cervical dystonia: a three years’ experience. Mov Disord 1992;7:135 (Abstract). Gonnering, 1988, Negative antibody response to long-term treatment of facial spasm with botulinum toxin, Am. J. Ophthalmol., 105, 313, 10.1016/0002-9394(88)90016-5 Greene, 1994, Development of resistance to botulinum toxin type A in patients with torticollis, Mov. Disord., 9, 213, 10.1002/mds.870090216 Jankovic, 1993, Longitudinal experience with botulinum toxin injections for the treatment of blepharospasm and cervical dystonia, Neurology, 43, 834, 10.1212/WNL.43.4.834 Zuber, 1993, Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance, Neurology, 43, 1715, 10.1212/WNL.43.9.1715 Borodic G, Pearce B, Duane D, Johnson E. Antibodies to botulinum toxin. Neurology 1995;45:204 (Letter). Aoki KR. Preclinical update on BOTOX® (Botulinum toxin type A) purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 1999 (in press). Boyd, 1997, Botulinum toxin A in the management of children with cerebral palsy: indications and outcome, Eur. J. Neurol., 4, S15 Heinen, 1997, Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A, Neuropediatrics, 28, 307, 10.1055/s-2007-973721 Heinen, 1995, Dystonic posture of lower extremities associated with myelomeningocele: successful treatment with botulinum A toxin in a six-month-old child, Neuropediatrics, 26, 214, 10.1055/s-2007-979757 Russell, 1989, The gross motor function measure: a means to evaluate the effects of physical therapy, Dev. Med. Child Neurol., 31, 341, 10.1111/j.1469-8749.1989.tb04003.x Boyd, 1998, Validity of a clinical measure of spasticity in children with cerebral palsy in a double-blinded randomised controlled clinical trial. American Academy of Cerebral Palsy Portland (AACPDM) [abstract], Dev. Med. Child Neurol., 40, 7 Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl. 4):523–35. Bohannon, 1987, Interrater reliability of a modified Ashworth scale of muscle spasticity, Phys. Ther., 67, 206, 10.1093/ptj/67.2.206 Erhardt, 1981, A developmental prehension assessment for handicapped children, Am. J. Occup. Ther., 35, 237, 10.5014/ajot.35.4.237 Trombly, 1995 Mathiowetz, 1985, Box and block test of manual dexterity: norms for 6–19 year olds, Can. J. Occup. Ther., 52, 241, 10.1177/000841748505200505 Wissel, 1999, Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of ‘high-dose’ versus ‘low-dose’ treatment, Neuropediatrics, 20, 1 Eames, 1999, The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response, Dev. Med. Child Neurol., 41, 226, 10.1017/S0012162299000493 Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2000;42:1–10. Corry IS, Cosgrove AP, Duffy CM, Taylor TC, Graham HK. Botulinum toxin A in hamstring spasticity. Gait Post 1999;10:206–10. Massin, 1999, Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection, J. Ped. Orthopaed., 19, 362, 10.1097/01241398-199905000-00015 Sutherland DH, Kaufman KR, Wyatt MD, Chambers HG, Mubarak SJ. Double-blind study of Botulinum Toxin type A injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Post 1999;10:1–9 Boyd RN, Graham JEA, Nattrass GR, Graham HK. Medium term outcome-response characterisation and risk factor analysis of Botulinum Toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999;6(Suppl. 4):S37–45.